Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production

Rheumatology (Oxford). 2008 Jul;47(7):1104-5. doi: 10.1093/rheumatology/ken175. Epub 2008 May 20.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Churg-Strauss Syndrome / drug therapy*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interleukin-5 / biosynthesis*
  • Male
  • Rituximab
  • T-Lymphocytes / drug effects*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Interleukin-5
  • Rituximab